AstraZeneca Links Up With Targacept In $1.2B Deal
Under the collaboration and license deal announced Thursday, AstraZeneca will make an up-front payment of $200 million upon effectiveness of TC-5214, Targacept’s late-stage investigational drug for major depressive disorder.
Winston-Salem, N.C.-based Targacept will collect an additional $540 million if certain development, regulatory and initial commercial sale targets are met. The biotech firm also stands to...
To view the full article, register now.